secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0001601485-23-000057
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Therapeutics receives $2.6M grant from GI Research Foundation for two cancer vaccines
--------------------------------------------------------------------------------

- Grant awarded on Sept 7, 2023, adds to $2.8M received in Sept 2022 from GIRF.
- Funds will advance ELI-007 (mutant BRAF-peptide) and ELI-008 (p53 hotspot mutation-peptide) vaccines.
- Vaccines use Elicio's AMP lymph node-targeting platform; CMC, regulatory, and clinical prep underway.
- BRAF V600E mutations seen in 40% melanoma, 10% colon, 2% lung; p53 mutations in ~30% solid tumors.
- Non-dilutive funding supports IND planning and initial patient clinical assessment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000057/0001601485-23-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000057/angn-20230907.htm
  HTML page:      https://secwatch.observer/filing/0001601485-23-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer